

4th International Conference on Tissue Science and Regenerative Medicine

July 27-29, 2015 Rome, Italy

Safety study of intravenously administered human cord blood stem cells in the treatment of symptoms related to chronic inflammation

Brian M Mehling¹, Louis Quartararo¹, Marine Manvelyan¹, Paul Wang¹ and Dong-Cheng Wu^{2,3}

¹Blue Horizon International LLC, USA

²Wuhan University, China

³Wuhan Hongqiao Brain Hospital, China

Stem cell research plays an important role in orthopedic regenerative medicine today. Arthritis literally means “inflammation of a joint”. Mesenchymal Stem Cells (MSCs) represent a valuable tool for therapy of symptoms related to chronic inflammatory diseases. Blue Horizon Stem Cell Therapy Program is a leading provider of adult and children’s stem cell therapies. The purpose of this study is primarily to monitor the immune response in order to validate the safety of intravenous infusion of human umbilical cord blood derived MSCs (UC-MSCs) and secondly to evaluate effects on biomarkers associated with chronic inflammation. Our study of blood test markers of 9 patients with chronic inflammation before and within three months after MSCs treatment demonstrates that there is no significant changes and MSCs treatment was safe for the patients. Analysis of different indicators of chronic inflammation included in initial 24-hours, two weeks and three months protocols showed that stem cell treatment was safe for the patients. Further close monitoring and inclusion of more patients are necessary to fully characterize the advantages of UC-MSCs application in treatment of symptoms related to chronic inflammation.

Biography

Brian M Mehling is a practicing American orthopedic trauma surgeon, researcher, and philanthropist. He is spearheading groundbreaking research in stem cell therapy through his company, Blue Horizon International, a healthcare consulting organization focused on treatment and research using stem cells. He started his path in medicine through undergraduate study at Harvard University, obtaining his Bachelor of Arts and Master of Science degrees in Biochemistry from Ohio State University. Completing his degree of medicine at Wright State University School of Medicine, he received post graduate education through residencies and fellowships at St. Joseph’s Hospital in Paterson, NJ and the Graduate Hospital in Philadelphia, PA, while pursuing a PhD in Chemistry. An orthopedic trauma surgeon, he operates his own practice, Mehling Orthopedics, in both West Islip, NY and Hackensack, NJ. He is also on call at Good Samaritan Hospital, Hackensack University Medical Center, Hackensack University Medical Center at Pascack Valley, St. Joseph’s Medical Center, and St. Joseph’s Wayne Medical Center. He has traveled extensively throughout Asia and the Middle East observing first hand the differences in healthcare standards. Identifying the need for a universal high quality standard, he founded Blue Horizon International. He and his colleagues have successfully treated and monitored more than 600 patients using stem cell and regenerative therapies. Patients have been treated for a wide range of diseases and disorders including spinal cord injury and cerebral palsy. He founded the Blue Horizon Charitable Foundation to enhance the quality of health to those in need. Efforts are focused on helping human service and health organizations, while also providing resources benefitting children orphaned from war and disease. Apart from his organizations, he personally contributes his time and resources to charitable causes. He has sponsored patients’ trips to China for stem cell treatments, as well as hosting charitable events from his own homes in New York, the Hamptons, and France. Notable beneficiaries include The Sean Kimmerling Testicular Cancer Foundation and the Children of Chernobyl.

mmanvelyan@bluehorizonhospital.com

Notes: